DBV Technologies SA (DBVT)

15.02
0.36 2.30
NASDAQ : Health Technology
Prev Close 15.38
Open 15.00
Day Low/High 14.89 / 15.30
52 Wk Low/High 13.51 / 26.98
Volume 44.58K
Avg Volume 127.70K
Exchange NASDAQ
Shares Outstanding 58.38M
Market Cap 957.76M
EPS -3.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.

DBVT Rises On Data for Peanut Allergy Drug; Bitcoin Rockets Past $8,000 -- ICYMI

DBVT Rises On Data for Peanut Allergy Drug; Bitcoin Rockets Past $8,000 -- ICYMI

Here's what you need to know now for Monday, Nov. 20.

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

Here's what you need to know now for Monday, Oct. 23.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Synergy Pharmaceuticals, Bluebird Bio and DBV Technologies were among the biotech stock movers in early trading on Friday.

These Stocks Are Trending Up With Monster Volume

These Stocks Are Trending Up With Monster Volume

Let's take a look at several stocks that are experiencing unusual volume activity.

7 Stocks Trending Up With Monster Volume

7 Stocks Trending Up With Monster Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.

DBV Technologies, BioNet-Asia And Geneva University Hospitals Complete Dosing In First Cohort Of Phase I Study Of Viaskin RPT For Booster Vaccination Against Pertussis

DBV Technologies, BioNet-Asia And Geneva University Hospitals Complete Dosing In First Cohort Of Phase I Study Of Viaskin RPT For Booster Vaccination Against Pertussis

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), the Geneva University Hospitals (HUG) and BioNet-Asia Co.

DBV Technologies Announces Poster Presentations At The 2016 American College Of Allergy, Asthma, And Immunology Meeting

DBV Technologies Announces Poster Presentations At The 2016 American College Of Allergy, Asthma, And Immunology Meeting

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced the presentation of two posters on its Viaskin Peanut development program at the American College of Allergy, Asthma, and...

DBV Technologies To Attend Upcoming Investor Conferences

DBV Technologies To Attend Upcoming Investor Conferences

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced that members of its management team will present and host investor meetings at the following upcoming investor events:...

DBV Technologies Completes Enrollment Of Phase II Study Of Viaskin Milk For The Treatment Of Milk Allergic Patients

DBV Technologies Completes Enrollment Of Phase II Study Of Viaskin Milk For The Treatment Of Milk Allergic Patients

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced that enrollment for Part B, or Phase II, of the Phase I/II study of Viaskin Milk for the treatment of patients with...

DBV Technologies Reports September 30, 2016 Cash Position

DBV Technologies Reports September 30, 2016 Cash Position

DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced its cash and cash equivalents as of September 30, 2016.

DBV Technologies Announces Publication Of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study In The Journal Of Allergy And Clinical Immunology

DBV Technologies Announces Publication Of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study In The Journal Of Allergy And Clinical Immunology

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced the publication of 12-month results from CoFAR6, a Consortium of Food Allergy Research (CoFAR) study sponsored by the...

Topline Results From Two-Year Follow-Up Study Of Viaskin Peanut Show Long-Lasting And High Levels Of Desensitization To Peanut

Topline Results From Two-Year Follow-Up Study Of Viaskin Peanut Show Long-Lasting And High Levels Of Desensitization To Peanut

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced topline results from the two-year OLFUS-VIPES study supporting the durable effect and favorable safety profile of Viaskin...

DBV Technologies Receives FDA Fast Track Designation For Viaskin Milk For The Treatment Of Cow's Milk Protein Allergy

DBV Technologies Receives FDA Fast Track Designation For Viaskin Milk For The Treatment Of Cow's Milk Protein Allergy

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced that the U.

DBV Technologies Announced Results Of Its 2016 Annual Meeting Of Shareholders

DBV Technologies Announced Results Of Its 2016 Annual Meeting Of Shareholders

Adoption of all resolutions submitted to the vote of Shareholders

DBV Technologies Announces Appointment Of Leading Japanese Allergist, Dr. Motohiro Ebisawa, To Its Scientific Advisory Board

DBV Technologies Announces Appointment Of Leading Japanese Allergist, Dr. Motohiro Ebisawa, To Its Scientific Advisory Board

Dr. Ebisawa strengthens DBV's scientific expertise and its global leadership in developing treatments for food allergies